Key facts
- Skyhawk Therapeutics announced 12-month interim results for the SKY-0515 clinical trial.
- The trial is for Huntington's disease.
- Results showed an improvement of +0.38 in composite UHDRS scores compared to a baseline.
- This contrasts with an expected decline of -0.92 points based on natural history analyses.
Skyhawk Therapeutics has released twelve-month interim results from its Phase 1/2 clinical trial for SKY-0515, a treatment for Huntington's disease. The data indicates a positive trend, with an improvement of +0.38 in composite Unified Huntington's Disease Rating Scale (cUHDRS) scores from baseline. This contrasts with expected natural history analyses, which projected a decline of -0.92 points over a similar period. The trial is in its early stages, and these are provisional findings.